Can a vaccine stop oral HPV in men with HIV?
NCT ID NCT04255849
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto Nacional de Salud Pública, Mexico
Cuernavaca, Morelos, 62209, Mexico
-
Universidade de São Paulo
São Paulo, São Paulo, 05403-911, Brazil
-
University of Puerto Rico AIDS Clinical Trials Unit
San Juan, Purto Rico, 00935, Puerto Rico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
- Can a single HIV pill tame the epidemic in africa?
- Could a shorter drug course beat a longer one for a deadly fungal infection?
- A kinder, more personal touch may help people with HIV stay in care — a large trial in zambia puts it to the test
- Can tracking HIV's genetic fingerprints reveal where the epidemic is heading?
- Robotic surgery may spare throat cancer patients from chemo and radiation